Sustainable and Scalable Strategies for Safe and Effective Administration of Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma in Outpatient and Community Settings - CME

CME

Title: Sustainable and Scalable Strategies for Safe and Effective Administration of Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma in Outpatient and Community Settings

Description: Multiple myeloma (MM) remains incurable. Despite advances in treatment and aggressive first-line therapy, most patients relapse. The pursuit for tolerable and effective treatments for heavily treated patients in the relapsed/refractory (R/R) setting has resulted in novel targets and therapies, including four bispecific antibodies (BsAbs). Because these agents have unique adverse event profiles which can be life-threatening, patients are typically hospitalized during step-up dosing to ensure proper pretreatment, monitoring, and supportive care. Many institutions are piloting outpatient administration of BsAbs to increase access to, reduce inpatient hospitalizations, lower overall healthcare costs, and enhance patients’ experiences. Yet administration of BsAbs in community settings is challenged by lack of experience coupled with requirements for multidisciplinary care and poorly aligned infrastructures. This activity supports community providers in assessing their infrastructure, protocols, and workforce to implement the clinical and operational elements necessary for safe and effective outpatient BsAb administration. This activity also engages academic providers to support improved care coordination and transitions as well as mentoring of community specialists.

Target Audience: This educational activity is designed for community and academic hematologists/oncologists, as well as hematology/oncology clinical pharmacists, NPs and PAs in the oncology setting, oncology nurses and other members of the multidisciplinary rapid response team including members of the ED, ICU, and infectious disease teams in the community settings who care for/manage patients with R/R MM.

Learning Objectives

Community Oncology Sites:
- Align site infrastructure and build clinical capacity for safe and effective BsAb administration in community settings to address patient selection, step-up dosing criteria, treatment maintenance, and AE monitoring and management protocols
- Develop transition of care protocols to and from academic center providers to address referrals of eligible patients and outpatient administration of BsAbs
- Establish multidisciplinary care pathways, workflows, and training requirements to ensure optimal alignment to evidence-based care at each step in the treatment process
Individual multidisciplinary learners practicing in community settings:
- Integrate the latest evidence-based decision support tools and strategies to formulate individualized management plans for patients with R/R MM
- Employ strategies to prevent, monitor, and manage AEs associated with BsAbs
- Adopt patient-centric education and communication materials on BsAbs for the treatment of R/R MM
Individual hematologists/oncologists in academic settings:
- Foster a culture of mentorship and leadership to facilitate learning and optimal coordination of care between community and academic centers

Disclosures and Disclaimers: The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s). This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis. This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL and The University of Chicago require the speaker to disclose that a product is not labeled for the use under discussion.

Accredited Providers

Commercial Support

Credit Information

Credit Type	Units / Unit Type	Board
AMA PRA Category 1 Credit	4.5 Credits	ACCME- Accreditation Council for Continuing Medical Education